Market Cap 2.60B
Revenue (ttm) 376.07M
Net Income (ttm) -16.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 143.13
Profit Margin -4.29%
Debt to Equity Ratio 0.58
Volume 1,172,900
Avg Vol 1,572,654
Day's Range N/A - N/A
Shares Out 125.08M
Stochastic %K 47%
Beta 1.51
Analysts Strong Sell
Price Target $34.62

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 418 5006
Address:
3027 Townsgate Road, Suite 300, Westlake Village, United States
ZManicItalian
ZManicItalian Jun. 4 at 7:55 PM
$ARQT added a little more, thinking it may not take another leg lower 🤔
0 · Reply
Merlintrader
Merlintrader Jun. 4 at 12:29 PM
$ACHV $ARQT $VRDN JUNE PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/
0 · Reply
Neutin
Neutin Jun. 4 at 6:49 AM
$ARQT Yooo, is anyone here? Sleeping as usual, I see. 😆
0 · Reply
BiltmoreAz
BiltmoreAz May. 28 at 12:58 AM
$ARQT Give us long term holders the buyout here in 2026. Ill take 30 a share. Sub 5 average. It will happen someday, oh well i just keep holding it!
1 · Reply
Neutin
Neutin May. 27 at 2:09 PM
$ARQT Why is nobody interested in this stock? Anyway, this looks like a good opportunity
1 · Reply
DonCorleone77
DonCorleone77 May. 26 at 6:58 PM
$ARQT Attached is a Mizuho analyst note regarding ARQT issued today.
0 · Reply
Damian23
Damian23 May. 25 at 3:12 PM
$ARQT Revenue path: $487M (2026) → $1.3B peak (2033) But using 35% FCF margin at scale (justified by 91% gross margin + leveraged opex) PV of 10yr FCFs 35% margin: ~$1.82B Terminal value (2.5% growth, 10.5% WACC): ~$2.20B EV ≈ $4.0B | Add net cash $122M = equity $4.1B ÷ 129.4M shares = ~$31.70/share Or on pure EV/peak sales: Peak sales $1.3B × 3× multiple = $3.9B EV Add net cash → equity $4.0B ÷ 129M = ~$31/share Peak sales $1.8B × 3× = $5.4B → ~$42/share Bear (20% FCF margin): ~$19 Central (35% FCF margin, $1.3B peak): ~$32 Bull (35% FCF margin, $1.8B peak): ~$42 Current price ~$21.73 → 45–90% upside to fair value
2 · Reply
Rhody27
Rhody27 May. 22 at 7:10 PM
$ARQT anemic volume today.
0 · Reply
DavyDaveCharts
DavyDaveCharts May. 21 at 9:58 PM
$ARQT monthly: if bulls can turn the imbalance into a discount we get a right shoulder. That, in turn, gives liquidity draw to 41 a chance.
1 · Reply
liadanielle
liadanielle May. 21 at 3:19 PM
0 · Reply
Latest News on ARQT
Arcutis Biotherapeutics reports Q1 EPS (9c), consensus (6c)

2026-05-07T01:26:52.000Z - 4 weeks ago

Arcutis Biotherapeutics reports Q1 EPS (9c), consensus (6c)


Arcutis Biotherapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2026


Arcutis Biotherapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Arcutis Biotherapeutics Earnings release: Q1 2026


Arcutis Biotherapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Arcutis Biotherapeutics Quarterly report: Q1 2026


Arcutis Biotherapeutics Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Arcutis Biotherapeutics Slides: Q1 2026


Arcutis Biotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Arcutis Biotherapeutics Proxy statement: Proxy filing


Arcutis Biotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Arcutis Biotherapeutics Proxy statement: Proxy filing


Arcutis Biotherapeutics Slides: Corporate presentation

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Arcutis Biotherapeutics Slides: Corporate presentation


Arcutis Biotherapeutics files automatic mixed securities shelf

2026-02-25T21:51:17.000Z - 3 months ago

Arcutis Biotherapeutics files automatic mixed securities shelf


Arcutis Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q4 2025


Arcutis Biotherapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Arcutis Biotherapeutics Annual report: Q4 2025


Arcutis Biotherapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Arcutis Biotherapeutics Earnings release: Q4 2025


Arcutis Biotherapeutics Slides: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Arcutis Biotherapeutics Slides: Q4 2025


Arcutis Biotherapeutics reports Q4 EPS 13c, consensus 9c

2026-02-25T21:08:30.000Z - 3 months ago

Arcutis Biotherapeutics reports Q4 EPS 13c, consensus 9c


Arcutis announces Max Homa joins ‘Free to Be Me’ campaign

2026-02-24T14:27:28.000Z - 3 months ago

Arcutis announces Max Homa joins ‘Free to Be Me’ campaign


Arcutis Biotherapeutics Transcript: Q3 & Investor Day 2025

Oct 28, 2025, 10:30 AM EDT - 7 months ago

Arcutis Biotherapeutics Transcript: Q3 & Investor Day 2025


Arcutis Biotherapeutics Earnings release: Q3 2025

Oct 28, 2025, 10:30 AM EDT - 7 months ago

Arcutis Biotherapeutics Earnings release: Q3 2025


Arcutis Biotherapeutics Quarterly report: Q3 2025

Oct 28, 2025, 10:30 AM EDT - 7 months ago

Arcutis Biotherapeutics Quarterly report: Q3 2025


Arcutis Biotherapeutics Slides: Q3 2025

Oct 28, 2025, 10:30 AM EDT - 7 months ago

Arcutis Biotherapeutics Slides: Q3 2025


Arcutis to Present at Upcoming Investor Conferences

Oct 27, 2025, 4:00 PM EDT - 7 months ago

Arcutis to Present at Upcoming Investor Conferences


Arcutis Biotherapeutics Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 8 months ago

Arcutis Biotherapeutics Slides: Corporate Presentation


Arcutis Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Arcutis Biotherapeutics Earnings Call Transcript: Q2 2025


Arcutis Biotherapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Arcutis Biotherapeutics Quarterly report: Q2 2025


Arcutis Biotherapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Arcutis Biotherapeutics Earnings release: Q2 2025


Arcutis Biotherapeutics Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Arcutis Biotherapeutics Slides: Q2 2025


Arcutis Biotherapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Earnings Call Transcript: Q1 2025


Arcutis Biotherapeutics Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Quarterly report: Q1 2025


Arcutis Biotherapeutics Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Earnings release: Q1 2025


Arcutis Biotherapeutics Slides: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Arcutis Biotherapeutics Slides: Q1 2025


Arcutis Biotherapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Arcutis Biotherapeutics Proxy statement: Proxy Filing


Arcutis Biotherapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Arcutis Biotherapeutics Proxy statement: Proxy Filing


Arcutis Announces Chief Financial Officer Transition

Apr 10, 2025, 4:30 PM EDT - 1 year ago

Arcutis Announces Chief Financial Officer Transition


Arcutis and Padagis Agree to Stay Patent Lawsuit

Apr 2, 2025, 1:16 PM EDT - 1 year ago

Arcutis and Padagis Agree to Stay Patent Lawsuit


ZManicItalian
ZManicItalian Jun. 4 at 7:55 PM
$ARQT added a little more, thinking it may not take another leg lower 🤔
0 · Reply
Merlintrader
Merlintrader Jun. 4 at 12:29 PM
$ACHV $ARQT $VRDN JUNE PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/
0 · Reply
Neutin
Neutin Jun. 4 at 6:49 AM
$ARQT Yooo, is anyone here? Sleeping as usual, I see. 😆
0 · Reply
BiltmoreAz
BiltmoreAz May. 28 at 12:58 AM
$ARQT Give us long term holders the buyout here in 2026. Ill take 30 a share. Sub 5 average. It will happen someday, oh well i just keep holding it!
1 · Reply
Neutin
Neutin May. 27 at 2:09 PM
$ARQT Why is nobody interested in this stock? Anyway, this looks like a good opportunity
1 · Reply
DonCorleone77
DonCorleone77 May. 26 at 6:58 PM
$ARQT Attached is a Mizuho analyst note regarding ARQT issued today.
0 · Reply
Damian23
Damian23 May. 25 at 3:12 PM
$ARQT Revenue path: $487M (2026) → $1.3B peak (2033) But using 35% FCF margin at scale (justified by 91% gross margin + leveraged opex) PV of 10yr FCFs 35% margin: ~$1.82B Terminal value (2.5% growth, 10.5% WACC): ~$2.20B EV ≈ $4.0B | Add net cash $122M = equity $4.1B ÷ 129.4M shares = ~$31.70/share Or on pure EV/peak sales: Peak sales $1.3B × 3× multiple = $3.9B EV Add net cash → equity $4.0B ÷ 129M = ~$31/share Peak sales $1.8B × 3× = $5.4B → ~$42/share Bear (20% FCF margin): ~$19 Central (35% FCF margin, $1.3B peak): ~$32 Bull (35% FCF margin, $1.8B peak): ~$42 Current price ~$21.73 → 45–90% upside to fair value
2 · Reply
Rhody27
Rhody27 May. 22 at 7:10 PM
$ARQT anemic volume today.
0 · Reply
DavyDaveCharts
DavyDaveCharts May. 21 at 9:58 PM
$ARQT monthly: if bulls can turn the imbalance into a discount we get a right shoulder. That, in turn, gives liquidity draw to 41 a chance.
1 · Reply
liadanielle
liadanielle May. 21 at 3:19 PM
0 · Reply
5StarTrader
5StarTrader May. 21 at 2:52 PM
$ARQT Institutions owned 112.53% of all issued shares of ARQT as of 3.31.2026, having added more than 25m shares to their portfolios in a brief 90 day period. The results? The stock price was (mysteriously) driven down while the Market Maker Mafia filled their limit orders from their clients who expect favors for giving them their orders, aka., “big-fat-fees-for-favors” deals. To fill those time limit orders & earn those “big-fat-fees-for-favors”, the Mafiosos create counterfeit shares & assume the risk that they can manipulate the stock price, like it’s another OpEx Friday, so that novice investors will give them their shares at prices the Mafiosos offer them, because the Mafia sets their prices for the Bid & Offer at whatever price they believe benefits themselves. You see, they know retail reads & believes their “technical messaging” of “our offer today will be lower tomorrow, so you better surrender your shares today”, omitting, “…so we can cover our naked short positions.”
0 · Reply
Neutin
Neutin May. 21 at 1:44 PM
$ARQT Bullish
0 · Reply
ZManicItalian
ZManicItalian May. 20 at 4:02 PM
$ARQT let's V-bottom out of here soon, eh? Looks like there has recently been a 5 wave downdraft that is ending. Time for buyers to step back in 🤔
0 · Reply
ZManicItalian
ZManicItalian May. 20 at 3:50 PM
$ARQT good day to add 🍻🐂
0 · Reply
JazzyJ03
JazzyJ03 May. 20 at 3:03 PM
$ARQT I’ve been here a long time & I’m not going anywhere. Long.
0 · Reply
Franciscomaligno
Franciscomaligno May. 19 at 9:45 PM
$ARQT another big fact... AH volume is 573k , whilr usually is 30/40k , HUGE !!!! Something big is happening... JUMP IN !!!
1 · Reply
liadanielle
liadanielle May. 19 at 6:41 PM
$ARQT son of a bitch! Man, it’s like you could set your watch. You have good news and the stock plumets! Always happens! No choice but the buy a little more. Stick with this company though. I use their product. It’s wonderful. If they could get the cost down, this thing is a $50 stock for sure.
0 · Reply
Franciscomaligno
Franciscomaligno May. 19 at 6:25 PM
$ARQT I AGREE !!! MM's are trying to grab shares to retails. BO WILL COME VERY SOON !!!
0 · Reply
AdiKrononaut
AdiKrononaut May. 19 at 5:28 PM
$ARQT Bought some today
0 · Reply
5StarTrader
5StarTrader May. 19 at 2:42 PM
$ARQT Of course a profitable, well funded, successful company’s stock price always declines 33% following back to back blow out quarters with raised revenue forecasts and major new large TAM approvals for an award winning, market dominant, patented product addressing multiple indications with more products under development when Institutional Investors are aggressively adding shares and own a whopping 112.53% of all outstanding shares of the company. It’s almost as though the MM Mafia is desperately manipulating the share price trying to get retail investors to sell, because “someone must know something!” explanation for causing the share price to fall, triggering a Stop Loss Share Harvesting event, which would coincidentally help the MM Mafia to cover their significant 12.53% of issued shares naked short positions before a buyout offer is announced. 🤔 https://www.nasdaq.com/market-activity/stocks/arqt/institutional-holdings
1 · Reply
Rhody27
Rhody27 May. 18 at 3:27 PM
$ARQT I'm looking forward to the inevitable buyout.
1 · Reply
Luise01128
Luise01128 May. 13 at 7:37 PM
0 · Reply